Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients
Public ClinicalTrials.gov record NCT02730715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to study the effects that two standard of care immunosuppression induction regimens have on regulatory T cells (Treg) in live donor renal transplant recipients. Both regimens are currently used in this hospital for early immunosuppression induction but the effects on Treg numbers and function is not well understood and likely will impact long term immune function.
Study identification
- NCT ID
- NCT02730715
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2010
- Primary completion
- Mar 31, 2020
- Completion
- Mar 31, 2020
- Last update posted
- Aug 31, 2022
2010 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated KIDNEY TRANSPLANTATION trials
Other public records listing KIDNEY TRANSPLANTATION. Sorted by last update posted; newest first. Not a recommendation.
- NCT03674307: Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates Active, not recruiting
- NCT06824454: Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients Recruiting
- NCT07224763: Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD Recruiting
- NCT07446296: Kidney Transplant Improvement Through New Exercise Training to Increase Capacity Recruiting
- NCT06744647: Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation Recruiting
- NCT06552169: REgulatory T Cell Therapy to Achieve Immunosuppression REduction Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02730715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2022 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02730715 live on ClinicalTrials.gov.